semaglutide and eye blindness Ozempic Vision Loss Lawsuit [2026 Update] GLP 1 Blindness Risk |

It is a GLP-1 (glucagon-like peptide-1) receptor agonist used for maintaining blood glucose levels in patients with type 2 diabetes and weight loss management in people with obesity or overweight when used in combination with exercise and dietary changes

Fifth phase of the epidemiologic transition: the age of obesity and inactivity

A key mechanism is its effect on gastric emptying, which is the process of your stomach emptying its contents

Tirzepatide dampens these reward signals

As federal policies plan to widen access and lower the cost of these anti-obesity drugs through Medicare and Medicaid, their user base could increase by 7 million